search
Back to results

Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study

Primary Purpose

Hypertension

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Amlodipine
Chlorthalidone
Losartan
Sponsored by
Anthony J Viera, MD, MPH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Hypertension focused on measuring Hypertension, Blood Pressure, Ambulatory Blood Pressure Monitoring

Eligibility Criteria

30 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 30 years and ≤ 65 years
  • Most recent (within 14 days) clinic systolic BP 126-150 mm Hg
  • Able/willing to wear a BP monitor for 24 hours on multiple occasions
  • Able/willing to take daily anti-hypertensive medication if indicated
  • Able to read and speak English

Exclusion Criteria:

  • Pregnant or trying to become pregnant
  • Known heart disease
  • History of persistent atrial fibrillation
  • Currently taking antihypertensive medication
  • Currently taking Simvastatin > 20mg daily
  • Clinician recommends against participation

Sites / Locations

  • University of North Carolina

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Active Comparator

Arm Label

Usual Care

ABPM Guided

Arm Description

Participants in the usual care arm will have 2 ABPM sessions during the study, but ABPM will not be used to make a diagnosis or dictate anti-hypertensive treatment. Any recommendations for anti-hypertensive treatment will be made only via regular clinical care.

Participants in the ABPM-guided arm will undergo 3 ABPM sessions. Results of ABPM will be used to make diagnoses and dictate anti-hypertensive treatment as applicable. Anti-hypertensive medications may include: Amlodipine, Chlorthalidone and/or Losartan.

Outcomes

Primary Outcome Measures

24 Hour Blood Pressure Average at the End of 4 Month Participation.

Secondary Outcome Measures

Full Information

First Posted
April 16, 2014
Last Updated
December 19, 2016
Sponsor
Anthony J Viera, MD, MPH
Collaborators
North Carolina Translational and Clinical Sciences Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT02121041
Brief Title
Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study
Official Title
Comparative Effectiveness of Ambulatory Blood Pressure Monitoring vs Usual Care for Diagnosing and Managing Hypertension: A Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
December 2016
Overall Recruitment Status
Completed
Study Start Date
May 2014 (undefined)
Primary Completion Date
September 2015 (Actual)
Study Completion Date
July 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Anthony J Viera, MD, MPH
Collaborators
North Carolina Translational and Clinical Sciences Institute

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to compare the effectiveness of ambulatory blood pressure monitoring to usual care (blood pressure measurement in the office) in diagnosing and managing hypertension.
Detailed Description
The usual strategy for detecting hypertension-repeated office blood pressure (BP) measurements-is inefficient and inaccurate. When paired with ambulatory BP monitoring (ABPM), which takes a multitude of measurements over 24 hours, it is clear that office BP measurements may convey a falsely positive diagnosis known as white-coat hypertension. What is less well-known is that office BP measurements may also convey a falsely negative diagnosis termed masked hypertension (MH). That is, office BP may measure as normal, yet 24-hour ambulatory measurements show elevated BP. People with MH have cardiovascular risk that is similar to that of people with diagnosed hypertension, yet MH goes unrecognized, and therefore, untreated. Ultimately, identifying the best strategy for accurately detecting hypertension is vital to improving overall BP control and reducing cardiovascular events. Without a feasible ABPM strategy, MH will continue to go unrecognized and untreated. Participants enrolled in the study will be randomized to either the usual care group or the ABPM-guided group. All participants will have a baseline ABPM. ABPM will be used to make a diagnosis and determine anti-hypertensive treatment in the ABPM-guided group only. Participants in the ABPM-guided group will have a follow-up ABPM in 2 months. All participants will have a final ABPM 4 months after enrollment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, Blood Pressure, Ambulatory Blood Pressure Monitoring

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
28 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Usual Care
Arm Type
No Intervention
Arm Description
Participants in the usual care arm will have 2 ABPM sessions during the study, but ABPM will not be used to make a diagnosis or dictate anti-hypertensive treatment. Any recommendations for anti-hypertensive treatment will be made only via regular clinical care.
Arm Title
ABPM Guided
Arm Type
Active Comparator
Arm Description
Participants in the ABPM-guided arm will undergo 3 ABPM sessions. Results of ABPM will be used to make diagnoses and dictate anti-hypertensive treatment as applicable. Anti-hypertensive medications may include: Amlodipine, Chlorthalidone and/or Losartan.
Intervention Type
Drug
Intervention Name(s)
Amlodipine
Other Intervention Name(s)
Norvasc
Intervention Description
Amlodipine 5 mg or 10 mg
Intervention Type
Drug
Intervention Name(s)
Chlorthalidone
Other Intervention Name(s)
Thalitone
Intervention Description
Chlorthalidone 12.5 mg or 25 mg
Intervention Type
Drug
Intervention Name(s)
Losartan
Other Intervention Name(s)
Cozaar
Intervention Description
Losartan 50 mg or 100 mg
Primary Outcome Measure Information:
Title
24 Hour Blood Pressure Average at the End of 4 Month Participation.
Time Frame
Participants will be on study average of 4 months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 30 years and ≤ 65 years Most recent (within 14 days) clinic systolic BP 126-150 mm Hg Able/willing to wear a BP monitor for 24 hours on multiple occasions Able/willing to take daily anti-hypertensive medication if indicated Able to read and speak English Exclusion Criteria: Pregnant or trying to become pregnant Known heart disease History of persistent atrial fibrillation Currently taking antihypertensive medication Currently taking Simvastatin > 20mg daily Clinician recommends against participation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anthony J Viera, MD, MPH
Organizational Affiliation
University of North Carolina
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of North Carolina
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study

We'll reach out to this number within 24 hrs